– First co-registered and co-aligned IVUS-OCT Platform for Intravascular Imaging – Company Positioned for U.S. Commercial Launch in a Growing Intravascular Imaging Market Estimated at Over $1 Billion
Other News
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes
Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round
NEW YORK, April 20, 2026 /PRNewswire/ — Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by…
Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors
Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., April 8, 2026 /PRNewswire/ — Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and […]
Corify Care Receives FDA Clearance for ACORYS® — Introducing Instant, 4-D Electroanatomical Cardiac Mapping in Real-time
MADRID, April 17, 2026 /PRNewswire/ — Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS® System, the first imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac…
Rapid Medical™ Announces FDA Clearance of TIGERTRIEVER™ 25 and First Clinical Cases
SOUTHLAKE, Texas & YOKNEAM, Israel–(BUSINESS WIRE)– #LVO–FDA clears TIGERTRIEVER™ 25 adjustable thrombectomy device by Rapid Medical; first U.S. cases show first-pass success in ischemic stroke.
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the risk of all-cause death was 57% lower for Foundayo vs. insulin glargine, showing the…
Nicklaus Children’s Hospital’s Heart Institute Performs Florida’s First Partial Heart Transplant
Among Nation’s First Programs to Offer the Innovative Procedure to Treat Valve Deformities in Children MIAMI, April 15, 2026 /PRNewswire/ — The cardiovascular surgery team at Nicklaus Children’s Hospital’s Heart Institute has successfully performed the first partial heart transplant in…
AccurKardia Announces Multi-Year Agreement with Specialized Medical to Power its State-of-the-Art Cardiac Monitoring Operations
NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced a multi-year agreement with Specialized Medical. Under this partnership, AccurKardia’s FDA-cleared Class II software as a medical device (SaMD), AccurECG™ 2.0, is actively powering Specialized Medical’s state-of-the-art cardiac monitoring operations, which currently serve more than 20 clinics, medical practices, and hospitals across four states. Specialized
Bunkerhill Health Secures CMS Reimbursement Pathway for AI Cardiovascular Analysis, Receives FDA Clearance for the First AI Algorithms to Evaluate Coronary and Aortic Valve Calcium on Contrast-Enhanced Chest CTs
SAN FRANCISCO–(BUSINESS WIRE)–Bunkerhill Health, an agentic AI company building healthcare’s system of action, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a new national billing code and associated payment under the Hospital Outpatient Prospective Payment System (OPPS) for algorithmic analysis of coronary artery calcium (CAC) and aortic valve calcium (AVC) on chest CT scans, effective April 1, 2026. The company also received U.S. Food and Drug Adm
Recent
VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
UBC MOSAIC and LifeLabs Unlock New Ways to Manage and Predict Heart Health
Popular
- No commented posts yet